Intratumoral injection of interferon gamma promotes the efficacy of anti-PD1 treatment in colorectal cancer
Authors:
- Xinyi ZhouXZXinyi Zhou
Open Access
- 11 March 2024
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 588, 216798
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 37 references indexed in Scilit:
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialThe Lancet, 2021
- Immune checkpoint inhibitors in melanomaThe Lancet, 2021
- MDSC: Markers, development, states, and unaddressed complexityImmunity, 2021
- Long non-coding RNAs in colorectal cancer: Novel oncogenic mechanisms and promising clinical applicationsCancer Letters, 2021
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal CancerJAMA Oncology, 2020
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and ToleranceTrends in Immunology, 2016
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Type 1 T Helper Cells Induce the Accumulation of Myeloid-Derived Suppressor Cells in the Inflamed Tgfb1 Knockout Mouse LiverHepatology, 2010
- Hierarchy of immunosuppressive strength among myeloid‐derived suppressor cell subsets is determined by GM‐CSFEuropean Journal of Immunology, 2009
- Primary Antitumor Immune Response Mediated by CD4+ T CellsImmunity, 2005